News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Aficamten retains upper hand over metoprolol for oHCM in subanalysis
14 Sep 2026
byAudrey Abella
Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.








